세계의 휴마로그(인슐린 리스프로) 시장 보고서(2025년) : 역학, 파이프라인 분석, 시장 인사이트 및 예측

Humalog (Insulin Lispro) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

US $ 4,490 ￦ 6,253,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,039,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,824,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

휴마로그(인슐린 리스프로) 시장 규모는 향후 몇 년 동안 강력한 성장을 보일 것으로 예상됩니다. 예측 기간의 성장은 맞춤형 의약품, 보험 지원, 전략적 협력, 디지털 건강 도구와의 통합, 신흥 시장의 확장에 기인할 수 있습니다. 예측 기간의 주요 동향으로는 가격 인하 및 경제성 개선 노력, 바이오시밀러 경쟁 제품 출시, 인슐린 전달 장치의 발전, 가격에 영향을 미치는 규제 변화, 원격 의료 및 디지털 건강의 확대 등이 있습니다.

당뇨병의 유병률 증가는 휴마로그(인슐린 리스프로) 시장의 성장을 촉진할 것으로 예상됩니다. 당뇨병은 인슐린 생산 부족 또는 인슐린 기능 장애로 인해 혈당 수치가 상승하는 만성 대사 장애입니다. 당뇨병의 증가는 주로 비만율의 증가, 앉아있는 생활 방식, 건강에 해로운 식습관, 인구 고령화, 도시화, 유전적 요인, 인식 및 진단 개선에 기인합니다. 휴마로그(인슐린 리스프로)는 식후 혈당 급증을 조절하고 합병증을 예방함으로써 당뇨병 관리에 중요한 역할을 합니다. 예를 들어, 2024년 3월 건강 개선 및 격차 사무소는 잉글랜드에서 1형 당뇨병 환자의 8개 치료 과정 수혜율이 2022년 35.2%에서 2023년 43.8%로 증가했다고 보고했습니다. 따라서 당뇨병의 유병률 증가는 휴마로그(인슐린 리스프로) 시장을 촉진하는 주요 요인입니다.

의료비 지출의 증가는 휴마로그(인슐린 리스프로) 시장의 성장을 촉진할 것으로 예상됩니다. 의료 지출은 개인, 정부, 민간 보험회사 및 기타 기관이 의료 서비스 및 제품에 할당하는 재정 자원을 의미합니다. 의료 지출의 증가는 인구 고령화, 의료 기술의 발전, 만성 질환의 증가 및 의료 수요의 증가에 의해 촉진되고 있습니다. 의료에 대한 투자가 증가하면 더 넓은 분배가 가능해지고, 환자 비용이 감소하며, 당뇨병 관리가 개선되어, 결과적으로 더 나은 건강 결과를 지원하고 의료 시스템에 대한 장기적인 재정적 부담을 줄일 수 있습니다. 예를 들어, 국가 통계국은 2022-2023년에 걸쳐 영국의 의료비 지출이 5.6% 증가하고, 2023년에는 지출 총액이 3,176억 3,000만 달러에 달한다고 보고했습니다. 이러한 의료비 지출 증가는 휴마로그(인슐린 리스프로) 시장의 성장에 기여하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 바이오의약품 시장에서의 제품 특성

• 분자 유형
• 투여경로(ROA)
• 작용기전(MOA)
• 안전성과 유효성

제4장 시장 동향과 전략

제5장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염, 경기 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제6장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 휴마로그(인슐린 리스프로) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 휴마로그(인슐린 리스프로) 시장 : 성장률 분석
• 세계의 휴마로그(인슐린 리스프로) 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 휴마로그(인슐린 리스프로) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 휴마로그(인슐린 리스프로) : 전체 시장 규모(TAM)

제7장 세계 시장의 가격 분석과 예측

제8장 시장 세분화

• 세계의 휴마로그(인슐린 리스프로) 시장 : 제품 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 인슐린 리스프로 프리필드 펜
• 인슐린 리스프로 용액 바이알
• 인슐린 리스프로 용액 카트리지
• 세계의 휴마로그(인슐린 리스프로) 시장 : 약제 클래스별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 휴마로그
• 애드멜로그
• 기타
• 세계의 휴마로그(인슐린 리스프로) 시장 : 적응증별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 1형 당뇨병
• 2형 당뇨병
• 임신성 당뇨
• 기타
• 세계의 휴마로그(인슐린 리스프로) 시장 : 연령층별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 소아
• 성인
• 노인
• 세계의 휴마로그(인슐린 리스프로) 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원 약국
• 소매 약국
• 온라인 약국

제9장 임상적응증 세계 시장 역학

• 약제의 부작용
• 임상적응증의 발병률과 유병률

제10장 지역별, 국가별 분석

• 세계의 휴마로그(인슐린 리스프로) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 휴마로그(인슐린 리스프로) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 한국 시장

제17장 서유럽 시장

제18장 영국 시장

제19장 독일 시장

제20장 프랑스 시장

제21장 동유럽 시장

제22장 북미 시장

제23장 미국 시장

제24장 캐나다 시장

제25장 남미 시장

제26장 중동 시장

제27장 아프리카 시장

제28장 경쟁 구도와 기업 프로파일

• 휴마로그(인슐린 리스프로) 시장 : 경쟁 구도
• 휴마로그(인슐린 리스프로) 시장 : 기업 프로파일
  • Eli Lilly and Company

제29장 세계 시장 : 파이프라인 분석

제30장 세계 시장 경쟁 벤치마킹과 대시보드

제31장 주요 인수합병(M&A)

제32장 최근 시장 동향

제33장 시장의 잠재력이 높은 국가, 전략

• 휴마로그(인슐린 리스프로) 시장(2029년) : 새로운 기회를 제공하는 국가
• 휴마로그(인슐린 리스프로) 시장(2029년) : 새로운 기회를 제공하는 부문
• 휴마로그(인슐린 리스프로) 시장(2029년) : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제34장 부록

HBR

영문 목차

영문목차

Humalog, also known as insulin lispro, is a fast-acting insulin primarily used to manage blood sugar levels in individuals with diabetes mellitus. Specifically designed to control post-meal blood sugar spikes, Humalog is administered subcutaneously, typically just before or after meals. This insulin analog is produced using recombinant DNA technology, making it a modified form of human insulin with altered amino acid sequences for quicker absorption.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary product types of Humalog (insulin lispro) include insulin lispro prefilled pens, insulin lispro solution vials, and insulin lispro solution cartridges. Insulin lispro prefilled pens are devices pre-loaded with insulin, offering convenient and accurate self-administration. The drug class includes Humalog, Admelog, and other similar products. Indications for use include type 1 diabetes, type 2 diabetes, gestational diabetes, and others. The age groups include pediatric, adult, and geriatric patients, with distribution channels spanning hospital pharmacies, retail pharmacies, and online pharmacies.

The humalog (insulin lispro) market research report is one of a series of new reports from The Business Research Company that provides humalog (insulin lispro) market statistics, including humalog (insulin lispro) industry global market size, regional shares, competitors with a humalog (insulin lispro) market share, detailed humalog (insulin lispro) market segments, market trends and opportunities, and any further data you may need to thrive in the humalog (insulin lispro) industry. This humalog (insulin lispro) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The humalog (insulin lispro) market size is expected to see strong growth in the next few years. It will grow to $13,118.7 million in 2029 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to personalized medicine, insurance support, strategic collaborations, integration with digital health tools, and expansion in emerging markets. Major trends in the forecast period include price reductions and affordability initiatives, introduction of biosimilar competitors, advancements in insulin delivery devices, regulatory changes impacting pricing, and expansion of telemedicine and digital health.

The increase in the prevalence of diabetes is expected to drive the growth of the humalog (insulin lispro) market. Diabetes is a chronic metabolic disorder characterized by elevated blood sugar levels due to insufficient insulin production or impaired insulin function. The rise in diabetes cases is primarily attributed to increasing rates of obesity, sedentary lifestyles, unhealthy diets, an aging population, urbanization, genetic factors, and improved awareness and diagnosis. Humalog (insulin lispro) plays a crucial role in managing diabetes by controlling post-meal blood sugar spikes and preventing complications. For instance, in March 2024, the Office for Health Improvement and Disparities reported a rise in the percentage of people with type 1 diabetes in England receiving 8 care processes, reaching 43.8% in 2023, up from 35.2% in 2022. Therefore, the growing prevalence of diabetes is a key factor driving the humalog (insulin lispro) market.

The rise in healthcare spending is expected to boost the growth of the humalog (insulin lispro) market. Healthcare spending refers to the financial resources allocated towards healthcare services and products by individuals, governments, private insurers, and other entities. The increase in healthcare spending is driven by an aging population, medical advancements, rising chronic diseases, and higher healthcare demand. This increased investment in healthcare enables wider distribution, lowers patient costs, and improves diabetes management, which, in turn, supports better health outcomes and reduces long-term financial burdens on healthcare systems. For example, the Office for National Statistics reported a 5.6% increase in UK healthcare spending between 2022 and 2023, with total expenditure reaching $317.63 billion in 2023. This rise in healthcare spending is contributing to the growth of the humalog (insulin lispro) market.

A key trend in the humalog (insulin lispro) market is the development of advanced products, such as rapid-acting analogue insulin, designed to enhance blood glucose control. These products feature improved formulations, faster onset times, and more precise dosing capabilities. Rapid-acting analogue insulins, like Humalog, are synthetic insulins that quickly lower blood glucose levels after meals, mimicking the body's natural insulin response. For example, in November 2022, Healthcare Pharmaceuticals Ltd., a Bangladesh-based company, launched Eli Lilly's Humalog 200 (Insulin Lispro 200 Units/ml) KwikPen in Bangladesh. This concentrated, rapid-acting insulin provides a more efficient solution for adults with both Type 1 and Type 2 diabetes, offering twice the insulin concentration and fewer pen changes per month.

Key player operating in the humalog (insulin lispro) market is Eli Lilly and Company

North America was the largest region in the humalog (insulin lispro) market in 2024. The regions covered in humalog (insulin lispro) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the humalog (insulin lispro) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The humalog (insulin lispro)market consists of sales of pre-filled pens, solution vials, and solution cartridges. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Humalog (Insulin Lispro) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on humalog (insulin lispro) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for humalog (insulin lispro) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The humalog (insulin lispro) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Insulin Lipro Prefilled Pen; Insulin Lipro Solution Vials; Insulin Lipro Solution Cartridges
• 2) By Drug Class: Humalog; Admelog; Other Drug Class
• 3) By Indication: Type 1 Diabetes; Type 2 Diabetes; Gestational Diabetes; Other Indications
• 4) By Age Group: Pediatric Patients; Adult Patients; Geriatric Patients
• 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: Eli Lilly and Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Humalog (Insulin Lispro) Market Characteristics

3. Humalog (Insulin Lispro) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Humalog (Insulin Lispro) Market Trends And Strategies

5. Humalog (Insulin Lispro) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Humalog (Insulin Lispro) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Humalog (Insulin Lispro) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Humalog (Insulin Lispro) Market Growth Rate Analysis
• 6.4. Global Humalog (Insulin Lispro) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Humalog (Insulin Lispro) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Humalog (Insulin Lispro) Total Addressable Market (TAM)

7. Global Humalog (Insulin Lispro) Market Pricing Analysis & Forecasts

8. Humalog (Insulin Lispro) Market Segmentation

• 8.1. Global Humalog (Insulin Lispro) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin Lipro Prefilled Pen
• Insulin Lipro Solution Vials
• Insulin Lipro Solution Cartridges
• 8.2. Global Humalog (Insulin Lispro) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Humalog
• Admelog
• Other Drug Class
• 8.3. Global Humalog (Insulin Lispro) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes
• Other Indications
• 8.4. Global Humalog (Insulin Lispro) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric Patients
• Adult Patients
• Geriatric Patients
• 8.5. Global Humalog (Insulin Lispro) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

9. Global Humalog (Insulin Lispro) Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Humalog (Insulin Lispro) Market Regional And Country Analysis

• 10.1. Global Humalog (Insulin Lispro) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Humalog (Insulin Lispro) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Humalog (Insulin Lispro) Market

• 11.1. Asia-Pacific Humalog (Insulin Lispro) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Humalog (Insulin Lispro) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Humalog (Insulin Lispro) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Humalog (Insulin Lispro) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Humalog (Insulin Lispro) Market

• 12.1. China Humalog (Insulin Lispro) Market Overview
• 12.2. China Humalog (Insulin Lispro) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Humalog (Insulin Lispro) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Humalog (Insulin Lispro) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Humalog (Insulin Lispro) Market

• 13.1. India Humalog (Insulin Lispro) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Humalog (Insulin Lispro) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Humalog (Insulin Lispro) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Humalog (Insulin Lispro) Market

• 14.1. Japan Humalog (Insulin Lispro) Market Overview
• 14.2. Japan Humalog (Insulin Lispro) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Humalog (Insulin Lispro) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Humalog (Insulin Lispro) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Humalog (Insulin Lispro) Market

• 15.1. Australia Humalog (Insulin Lispro) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Humalog (Insulin Lispro) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Humalog (Insulin Lispro) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Humalog (Insulin Lispro) Market

• 16.1. South Korea Humalog (Insulin Lispro) Market Overview
• 16.2. South Korea Humalog (Insulin Lispro) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Humalog (Insulin Lispro) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Humalog (Insulin Lispro) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Humalog (Insulin Lispro) Market

• 17.1. Western Europe Humalog (Insulin Lispro) Market Overview
• 17.2. Western Europe Humalog (Insulin Lispro) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Humalog (Insulin Lispro) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Humalog (Insulin Lispro) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Humalog (Insulin Lispro) Market

• 18.1. UK Humalog (Insulin Lispro) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Humalog (Insulin Lispro) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Humalog (Insulin Lispro) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Humalog (Insulin Lispro) Market

• 19.1. Germany Humalog (Insulin Lispro) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Humalog (Insulin Lispro) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Humalog (Insulin Lispro) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Humalog (Insulin Lispro) Market

• 20.1. France Humalog (Insulin Lispro) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Humalog (Insulin Lispro) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Humalog (Insulin Lispro) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Humalog (Insulin Lispro) Market

• 21.1. Eastern Europe Humalog (Insulin Lispro) Market Overview
• 21.2. Eastern Europe Humalog (Insulin Lispro) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Humalog (Insulin Lispro) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Humalog (Insulin Lispro) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Humalog (Insulin Lispro) Market

• 22.1. North America Humalog (Insulin Lispro) Market Overview
• 22.2. North America Humalog (Insulin Lispro) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Humalog (Insulin Lispro) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Humalog (Insulin Lispro) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Humalog (Insulin Lispro) Market

• 23.1. USA Humalog (Insulin Lispro) Market Overview
• 23.2. USA Humalog (Insulin Lispro) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Humalog (Insulin Lispro) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Humalog (Insulin Lispro) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Humalog (Insulin Lispro) Market

• 24.1. Canada Humalog (Insulin Lispro) Market Overview
• 24.2. Canada Humalog (Insulin Lispro) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Humalog (Insulin Lispro) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Humalog (Insulin Lispro) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Humalog (Insulin Lispro) Market

• 25.1. South America Humalog (Insulin Lispro) Market Overview
• 25.2. South America Humalog (Insulin Lispro) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Humalog (Insulin Lispro) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Humalog (Insulin Lispro) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Humalog (Insulin Lispro) Market

• 26.1. Middle East Humalog (Insulin Lispro) Market Overview
• 26.2. Middle East Humalog (Insulin Lispro) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Humalog (Insulin Lispro) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Humalog (Insulin Lispro) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Humalog (Insulin Lispro) Market

• 27.1. Africa Humalog (Insulin Lispro) Market Overview
• 27.2. Africa Humalog (Insulin Lispro) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Humalog (Insulin Lispro) Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Humalog (Insulin Lispro) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Humalog (Insulin Lispro) Market Competitive Landscape And Company Profiles

• 28.1. Humalog (Insulin Lispro) Market Competitive Landscape
• 28.2. Humalog (Insulin Lispro) Market Company Profiles
  • 28.2.1. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

29. Global Humalog (Insulin Lispro) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Humalog (Insulin Lispro) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Humalog (Insulin Lispro) Market

32. Recent Developments In The Humalog (Insulin Lispro) Market

33. Humalog (Insulin Lispro) Market High Potential Countries, Segments and Strategies

• 33.1 Humalog (Insulin Lispro) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Humalog (Insulin Lispro) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Humalog (Insulin Lispro) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer

관련자료